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ABSTRACT
The 3′-untranslated region of granulocyte/macrophage
colony-stimulating factor (GM-CSF) mRNA contributes
to the post-transcriptional regulation of gene express-
ion. Degradation is partly mediated by adenosine–
uridine-rich sequence elements (ARE), which serve as
binding sites for specific proteins. Stabilization of RNA
by phytohemagglutinin and concanavalin A treatment
is dependent on regulatory sequence elements
upstream of ARE. We have performed northwestern
blot and filter binding assays using cell extracts and
RNA sequences containing or lacking ARE. Murine
and human T cell extracts (EL-4 and Jurkat) yielded
two specific proteins of 93 and 94 kDa, respectively,
that were binding to sequences upstream of ARE.
Within this region, the human and murine RNA do not
share any obvious sequence identity, yet both are
target sites for the binding proteins. The smallest RNA
fragments protected by the proteins from RNase A
digestion, were 44 in the murine, and 38 ribonucleo-
tides long in the human sequence. The binding activity
of the 94 kDa protein derived from human Jurkat cells
could be enhanced by phytohemagglutinin. The inter-
action with regulatory mRNA sequences and the
responsiveness to phytohemagglutinin suggests that
the proteins are involved in controlling GM-CSF mRNA
turnover.
INTRODUCTION
Adenosine–uridine-rich sequence elements (ARE) located within
the 3′-untranslated region (3′UTR) of many cytokine, proto-
oncogene and other mRNAs, mediate rapid decay. Proteins
binding to such sequence elements have been identified and
characterized by several laboratories (1–10). In a few cases,
evidence has been presented that binding is related to a regulatory
function. Destabilizing properties were attributed to the AU-binding
protein AUF1 since it has been purified from post-ribosomal
supernatants that selectively accelerated degradation of c-myc
mRNA (3). A protease-sensitive factor protected interleukin-2
mRNA from rapid decay (10). The agonist induced increase of
β-adrenergic receptor mRNA binding protein correlated with a
destabilization of β-adrenergic receptor mRNA (11).
Concanavalin A (ConA), phytohemagglutinin (PHA), Ca2+
ionophore and the phorbol ester 12-O-tetradecanoyl-phorbol-13-
acetate (TPA) lead to an increased secretion of granulocyte/macro-
phage colony-stimulating factor (GM-CSF) in T cells (12,13).
The mechanisms leading to mRNA stabilization via pathways
acting through protein kinase C, protein kinase A, tyrosine kinase
or intracellular calcium release are greatly unknown. We have
studied protein kinase C- and Ca2+-mediated stabilization of
murine GM-CSF mRNA in T cells (12,14,15). Functional data
obtained for the post-transcriptional regulation of murine GM-CSF
expression, suggested that ARE-mediated decay alone is not
sufficient to explain TPA- and Ca2+ ionophore-mediated mRNA
stabilization. Complete decay of a chimeric chloramphenicol-acetyl-
transferase-GM-CSF mRNA required more sequence elements than
the cluster of AU-boxes located in the downstream half of the
GM-CSF 3′UTR. TPA-mediated stabilization of this chimeric
mRNA had an absolute requirement for sequences located in the
upstream half of the 3′UTR. Analysis of potential sequence-specific
RNA binding proteins to ARE of GM-CSF by either mobility-shift
or label-transfer experiments revealed a set of RNA–protein
complexes in the range of 33–42 kDa (1). These proteins
specifically recognized a 63 nt cluster of AUUUA motifs located
in the 3′ half of the murine and human GM-CSF 3′UTR. These
RNA–protein interactions, however, cannot explain the TPA-
mediated stabilization of the mRNA. Using a filter binding assay
and northwestern blotting techniques, we have now detected a 93
and a 94 kDa protein in murine and human T cells, respectively.
These proteins bound specifically to the sequence upstream of
ARE. The activity of the 94 kDa protein was enhanced in
PHA-treated Jurkat cells. These observations suggest that the
proteins are involved in the regulation of GM-CSF mRNA
turnover together with other cell-specific factors.
MATERIALS AND METHODS
Reagents
Reagents were purchased as follows: BSA and HEPES, Fluka
(Buchs SG, Switzerland); FBS, Amimed (Muttenz, Switzerland);
molecular mass standards, BioRad (Glattbrugg, Switzerland);
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MultiScreen membrane NP 0.2 µm, Millipore (Volketswil,
Switzerland); nitrocellulose membrane 0.45 µm, Schleicher &
Schuell (Riehen, Switzerland); penicillin and streptomycin, Life
Technologies (Basel, Switzerland); PHA was isolated from
soybeans; poly(I), Pharmacia (Dübendorf, Switzerland); RNase
A, RNase T1, yeast tRNA and SP6 RNA polymerase from
Boehringer Mannheim (Rotkreuz, Switzerland); RNase inhibitor
(RNasin), Promega (Wallisellen, Switzerland); tissue culture
RPMI 1640 medium, Inselspital Apotheke (Bern, Switzerland);
[α-32P]UTP (29.6 TBq, 800 Ci/mmol), Du Pont-New England
Nuclear (Regensdorf, Switzerland).
Cell cultures and protein extracts
All cell cultures were cultivated in a 5% CO2 incubator at 37C.
The murine thymoma cell line EL-4 (16) and the human T cell
lymphoma Jurkat (17) were grown in RPMI 1640 medium
supplemented with 10 % FBS, 2 mmol/l glutamine, 100 U/ml
penicillin and 100 µg/ml streptomycin. For stimulation, cells
were washed with PBS and resuspended at a density of 2 × 106
cells/ml in serum free RPMI 1640 medium. PHA was added to
obtain a concentration of 5 µg/ml. After the indicated period,
cellular metabolism was blocked on ice, cells were washed with
ice-cold PBS, and proteins were extracted. Cytoplasmic and
nuclear extracts were prepared according to methods described
previously (18). Cells were washed with PBS and kept on ice for
10 min in a buffer containing 25 mmol/l Tris–HCl, pH 7.4,
40 mmol/l KCl, 1% Triton X-100, 10 µg/ml leupeptin and
0.12 mmol/l PMSF. A pre-chilled glass Dounce homogenizer
was used to lyse the cells and nuclei were spun down at 3000 g.
The supernatant, designated the cytoplasmic extract, was centri-
fuged at 30 000 g at 4C for 1 h to remove debris. The nuclear
pellet was resuspended in a buffer containing 25 mmol/l
Tris–HCl, pH 7.4, 10 mmol/l KCl, 1 mmol/l MgCl2, 275 mmol/l
NaCl, 20% (v/v) glycerol, 10 µg/ml leupeptin, 0.12 mmol/l
PMSF and 0.5 mmol/l DTT. After two rounds of vortexing and
incubation on ice, the nuclear fraction was centrifuged at 18 000 g
for 1 min and the precipitate was discarded. Protein concentra-
tions were measured by standard protein assays. Lysates were
stored in aliquots at –70C until used.
Plasmid constructs and in vitro RNA synthesis
Sequences were derived from murine and human GM-CSF cDNAs
[Loci: MMGMCSF (19) and HSCSFGM (20), respectively] and
obtained by PCR amplification of plasmids pJL4GM5′∆19 (21)
and p9023 (20) with primers that included appropriate restriction
sites. Amplicons were ligated into the transcription vector
pSP64poly(A) (Promega). Murine sequence inserts from position
471 to 774, 471 to 658 and 497 to 556 were generated to construct
the plasmids pM23, pM21 and pM41, respectively. The transcribed
sequences thus contain either the entire murine GM-CSF 3′UTR
(muUTR), the 3′UTR lacking the ARE (murine upstream
regulatory elements, muURE) or the previously defined TPA-
response element (TRE). From the human sequence, an insert
from position 444 to 635 was generated to produce the plasmid
pM31. This sequence (huURE) corresponds to the murine
counterpart pM21. Plasmids were linearized upstream of the
poly(A) stretch and transcribed in vitro using SP6 polymerase and
a standard transcription protocol. For the synthesis of an unspecific
competitor riboprobe, the original pSP64poly(A) vector with the
Figure 1. Schematic diagram and aligned ribonucleotide sequences of murine
and human GM-CSF mRNA. Nucleotide numbers refer to GenBank accession
number X03221 for the murine and M10663 for the human sequence. AU-rich
sequence elements (ARE, underlined) and upstream regulatory sequence
elements (URE) are indicated in the murine and human 3′UTRs. In the murine
sequence, a 60 nt long functional phorbolester (TPA)-response element (TRE,
bold-face) lies within the URE.
intact multiple cloning site was linearized downstream of the
poly(A) sequence. Transcripts were gel purified on 6% polyacryl-
amide–8 M urea gels. Competitor RNA was produced by standard
large scale synthesis (RiboMAX, Promega).
Northwestern blotting
Cytoplasmic protein extracts were size separated by 12 or 7.5%
denaturing SDS–PAGE and electrotransferred to nitrocellulose
membranes (BA85, Schleicher & Schuell). Membrane-bound
proteins were renatured overnight at 20C in a buffer containing
10 mmol/l HEPES, pH 7.9, 40 mmol/l KCl, 5% glycerol, 0.2%
Nonidet-P40, 3 mmol/l MgCl2, 0.1 mmol/l EDTA, 1 mmol/l DTT
and 5 mg/ml BSA. Membranes were transferred to RNA binding
buffer (10 mmol/l HEPES, pH 7.9, 150 mmol/l KCl, 5 mmol/l
MgCl2, 8% glycerol, 0.2 mmol/l DTT, 50 µg/ml tRNA),
[α-32P]UTP-labeled RNA probe (6 × 106 c.p.m. for 3′UTR, 3 × 106
c.p.m. for URE) added, and membranes incubated for 2 h at 20C,
followed by digestion with RNase A (25 µg/ml) for 20 min at
37C. Membranes were washed twice with RNA binding buffer
without DTT and tRNA. Dry membranes were exposed for 1 h to
PhosphorImager (Molecular Dynamics, Inc.) screens. Digitized
images are presented in Figures 2, 4–6A and 7.
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Figure 2. Northwestern blot analyses of human and murine T cell extracts.
Sixty micrograms of cytoplasmic proteins from EL-4 (E) and Jurkat (J) cells
were separated by 12% SDS–PAGE and electrotransferred to nitrocellulose
membranes. After protein renaturation, membranes were probed with
[α-32P]UTP-labeled murine GM-CSF 3′UTR RNA (6 × 106 c.p.m.) in the
presence of 50 µg/ml tRNA (A). Autoradiograph in the presence of 1000-fold
molar excess of unlabeled muUTR RNA (B), and in the presence of vector
RNA sequence containing the 50 ribonucleotide long multiple cloning site of
pSP64poly(A) and a stretch of 30 adenylate residues (C). Molecular mass of
pre-stained protein markers are indicated.
Filter binding assay
Cytoplasmic protein extracts were incubated for 20 min at room
temperature with known amounts of in vitro transcribed,
[α-32P]UTP-labeled RNA probes (e.g. 0.06 ng = 3.6 × 10–13 mmol
= 15 000 c.p.m. of muUTR per reaction, specific activity
2.9–5.8 × 109 Bq/mg) in a binding buffer containing 10 mmol/l
HEPES, pH 7.6, 3 mmol/l MgCl2, 5% (v/v) glycerol, 1 mmol/l
DTT, 5 µg/reaction poly(I), 2 U/reaction RNasin. Reaction
mixtures were transferred to prewetted nitrocellulose membranes
(MultiScreen NP, Millipore) using a 96-well filtering device
(MultiScreen, Millipore) and incubated at 20C for 20 min.
Filters were washed with binding buffer supplemented with
200 mmol/l NaCl, transferred to scintillation vials, and counted in
a scintillation counter (LS 5000CE, Beckman, Nyon, Switzerland)
by Cerenkov counting. All reactions were assayed in duplicate.
Data in Figure 3 are mean values of two experiments.
Analyses of ribonuclease protected RNA fragments
Northwestern blots were treated with RNase A (25 µg/ml) for
20 min at 37C. RNA–protein complexes localized by autoradio-
graphy were cut out and RNA extracted from the complexes with
300 µl H2O and 200 µl phenol. After separation of the two phases
300 µl H2O was added to the phenol phase. The pooled aqueous
phases were extracted five times with 500 µl ether and their
volume was reduced by vacuum evaporation. RNA was separated
electrophoretically on sequencing gels together with polyribo-
nucleotide markers of known length. Markers were generated by
in vitro transcription in the presence of [α-32P]UTP. The dry gels
were exposed overnight to PhosphorImager screens.
Figure 3. Detection of ARE-independent binding using a filter binding assay.
Cytoplasmic proteins of EL-4 cells were incubated with radiolabeled RNA
from murine GM-CSF 3′UTR, URE (i.e., the 3′ untranslated region lacking the
AU-rich sequence elements) or ARE (A). Binding reactions were passed
through nitrocellulose membranes and complexed RNA retained on the filter
was determined by liquid scintillation counting. Cold competition experiments
were performed with muUTR (murine 3′ untranslated region) or muURE RNA
in a 104-fold molar excess (B). Data is represented as counts retained on the
membrane (A) or percentage (B) of retained versus input RNA (% radioactivity).
Mean values are derived from duplicate values of two independent experiments.
RESULTS
Detection of specific protein interactions with the GM-CSF
3′UTR 
The 3′UTR of GM-CSF mRNA has shown to be responsible for
the stabilization of the mRNA by TPA, lectins, calcium ionophore
A23187 and cytokines. The 3′UTR can be subdivided into two
regions, the ARE and the upstream regulatory sequence element
(URE) (Fig. 1A). The ARE of the human and the murine
sequences are almost identical, while the UREs differ significantly
(Fig. 1B). A functional TRE has been previously defined in
murine GM-CSF mRNA. By performing northwestern analyses
using the in vitro radiolabeled murine 3′UTR RNA probe, we
detected a specific interaction with a 93 kDa protein from extracts
of the murine thymoma EL-4 cell line, and with a 94 kDa protein
from human lymphoma Jurkat cells (Fig. 2A). Addition of
1000-fold molar excess of unlabeled muUTR RNA to the
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Figure 4. Competition analyses of murine sequences lacking AU-rich sequences (muURE) and murine sequences including the entire 3′UTR (muUTR) binding to
murine EL-4 (E) and human Jurkat (J) cell proteins on northwestern blots. Sixty micrograms of cytoplasmic protein extracts were incubated with either radiolabeled
muURE alone or in the presence of unlabeled muURE to compete binding of muUTR (A). Northwestern blots were incubated with radiolabeled muURE in presence
of increasing amounts of unlabeled muURE as competitor (B). Competition of the binding reaction with unlabeled RNA added 30 min after addition of the radioactive
muURE (C).
radiolabeled murine 3′UTR probe, almost completely abolished
the signals of the two proteins (Fig. 2B). In contrast, competition
with unlabeled vector sequence including a stretch of 30 adenylate
residues did not significantly affect binding of the two proteins
(Fig. 2C) suggesting that a specific interaction with muUTR RNA
had occurred. When cell extracts treated with proteinase K were
probed, no signals were obtained (data not shown).
Protein interaction is independent of ARE binding
To determine the site of the protein interactions within the 3′UTR,
three different radiolabeled probes were used. Ten micrograms
cytoplasmic proteins from EL-4 cell extracts were mixed with in
vitro synthesized radiolabeled murine UTR, URE (3′UTR lacking
ARE) or ARE RNA. Binding reactions were applied to nitrocellu-
lose filters and radioactivity of complexed RNA trapped on the
filters was determined (Fig. 3A). When the entire murine 3′UTR
(UTR) was added to the EL-4 protein extract, 74.3% (9196 c.p.m.
± 50, mean ± s.d.) was retained on the membrane. When the probe
lacking ARE (muURE) was used 68.3% (4188 ± 12 c.p.m.) was
measured, while a probe with only the AU-rich sequences (ARE)
yielded 52.5% (3410 ± 224 c.p.m.). Background radioactivity
was highest when ARE was used (4.6%) and lowest with URE
(1.7%). Subsequently, a series of competition experiments with
probes including either the entire 3′UTR or the 3′UTR lacking
ARE (URE) were performed in the presence of either none or
unlabeled muUTR or muURE RNA (Fig. 3B). In the absence of
competitor RNA, 42% of total labeled muUTR was retained,
while in the presence of 104-fold molar excess unlabeled muUTR
20% of the label was recovered. When muURE was used as
competitor instead, ∼24% of the total radioactivity was recovered.
Using a radioactive muURE probe, ∼56% of total counts were
retained on the filter. Competition with cold muURE and muUTR
RNA yielded 23 and 16% of initial counts. These results show
that binding of radiolabeled muUTR or muURE can be competed
to about the same levels by either unlabeled muUTR or muURE.
This suggests that most of the specific interaction between
binding proteins and the murine 3′UTR RNA sequence may
2421
Nucleic Acids Research, 1994, Vol. 22, No. 1Nucleic Acids Research, 1997, Vol. 25, No. 12 2421
Figure 5. Murine and human RNA compete for binding to 93 and 94 kDa
proteins. Cytoplasmic protein (60 µg per lane) from EL-4 (E) and Jurkat (J) cells
were separated by 12% SDS–PAGE, transferred to nitrocellulose and north-
western blot analysis performed. Membranes were incubated with [α-32P]UTP-
labeled murine and human URE RNA. Competition was carried out with
unlabeled huURE (350-fold molar excess) or muURE (200-fold molar excess).
occur in a region independent of ARE. The residual radioactivity
that cannot be quenched by cold competition suggests unspecific
binding of proteins to the GM-CSF mRNA 3′UTR.
Further competition reactions were analyzed by northwestern
blotting. Sixty micrograms cytoplasmic protein of EL-4 or Jurkat
cells was loaded per lane of a 12% SDS–PAGE, electrotransferred,
and after renaturation the binding reaction carried out with
radiolabeled muURE (Fig. 4A). As already observed with the
muUTR probe (Fig. 2A), muURE probe yielded a similar binding
pattern with the two major bands of 93 and 94 kDa. These bands
were almost completely abolished in the presence of the 3′UTR
probe and 500-fold molar excess unlabeled muURE. Thus,
muURE is able to compete the binding of muUTR to the 93 and
94 kDa proteins in EL-4 and Jurkat cells, respectively. In contrast,
other bands, especially in the 30 kDa range, were not affected by
muURE competition (Fig. 4A). Using a similar experimental
setup, the strength of the RNA–protein interaction was evaluated
by addition of radiolabeled muURE and various concentrations
of homologous cold muURE as competitor (Fig. 4B). The
northwestern analysis shows that a 100-fold molar excess was
needed to compete the binding completely. Again, as observed
before with muUTR probe, even at a 104-fold-excess of cold
muURE, non-specific binding to many proteins is not prevented.
This most likely reflects the incomplete competition observed in
the filter binding assay. In the experiments shown in Figure 4A
and B, blots were preincubated for 30 min with the unlabeled
competitor. In contrast, the competition experiment presented in
Figure 4C was performed by adding the cold competitor RNA
30 min after the labeled RNA. Specific competitor still abolished
the signal almost completely. This indicates that even after binding
to the 93 and 94 kDa proteins, the labeled RNA dissociates and
can be replaced by the unlabeled specific competitor.
Human and murine cross-reactivity
To investigate the presence of specific binding sites within the
URE of the human GM-CSF mRNA for RNA binding protein,
similar experiments as described above were carried out.
Figure 6. Characterization of the RNA binding site. Northwestern blots with
cytoplasmic protein from each EL-4 (E) and Jurkat cells (J) that were separated
by 7.5% SDS–PAGE and incubated with the functionally mapped 60 nt long
murine phorbolester (TPA)-response element (TRE). Increasing amounts of
unlabeled TRE were added as competitor (A). Human and murine URE RNA
(3′UTR lacking ARE) protected from RNase A digestion by human and murine
proteins were analyzed on a 12% sequencing gel (B). Synthetic polyribonucleo-
tides of known length were used as size markers. Arrows indicate smallest
protected fragments.
Northwestern blot analysis using radiolabeled huURE probe
revealed an identical banding pattern as seen for muURE (Fig. 5).
Competition of huURE binding to EL-4 and Jurkat cells proteins
with unlabeled muURE, or vice-versa, suppressed the signals of
the 93 and 94 kDa proteins (Fig. 5). In spite of any obvious
identity between muURE and huURE, the two proteins seem to
interact with both the murine and the human sequence.
Characterization of the RNA binding site
Northwestern analysis has provided data that the RNA binding
site for the two T cell proteins lies within the 187 nt long muURE.
To narrow down the binding area, a radiolabeled probe for the
previously identified functional 60 ribonucleotide TRE has been
used to evaluate specific binding (Figs 1 and 6A). The TRE probe
bound to the 93 and 94 kDa proteins. A 103–104-fold molar
excess of cold TRE had to be added to compete this binding
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Figure 7. Up-regulation of the human 94 kDa protein–RNA interaction by
PHA. Jurkat cells (2 × 106/ml) were left untreated or stimulated for 30 min with
PHA, proteins extracted and analyzed by northwestern blotting (7.5%
SDS–PAGE) with a radiolabeled huURE probe.
completely. Even at the highest concentration of cold competitor
used, the intensity of other bands remained unaffected. To further
analyze the binding area RNase A treatment of the binding
complex on the northwestern blot membranes was performed.
The protected fragments were recovered and separated electro-
phoretically on a sequencing gel. As calibrated by synthetic
polyribonucleotides, the murine EL-4 and Jurkat proteins yielded
smallest protected RNA fragments of 44 and 38 nt, respectively
(Fig. 6B).
Regulation of the URE binding proteins
The interaction of the 93 and 94 kDa proteins within the region
of the functional TRE suggests that these proteins are involved in
the control of mRNA turnover. To investigate if their synthesis or
binding activity can be modulated by cellular activation, the
effects of TPA, ConA and PHA were tested on human Jurkat and
murine EL-4 cells, murine NIH3T3 fibroblasts, human U937
promonocytes and fresh human peripheral blood mononuclear
cells. Cytoplasmic and nuclear extracts from treated and untreated
cells were compared by northwestern blot analyses. While no
signal was seen in human peripheral blood mononuclear cells, the
93 and 94 kDa proteins were detected in all other extracts (data
not shown). Unexpectedly TPA-stimulation did not induce
binding activity. A clear regulatory effect, however, was observed
in cytoplasmic extracts of Jurkat cells treated for 30 min with
PHA. Extracts from unstimulated cells probed with huURE
generated a weak signal of the 94 kDa protein, while upon PHA
stimulation the signal increased significantly (Fig. 7).
DISCUSSION
The results presented here show that murine and human T cells
contain a protein that binds specifically to the murine and human
GM-CSF mRNA 3′UTR. Under denaturing conditions, the
murine and the human protein have an apparent molecular mass
of ∼93 and 94 kDa, respectively. The size of the two proteins
differs markedly from other RNA binding proteins characterized
recently. The family of proteins with the capacity to bind with
high affinity to AU-rich, and in some cases U-rich regions, fall in
the range of 10–70 kDa molecules (1–3,6–10,22,23). Yet, RNA
binding proteins of larger sizes have also been reported, e.g., iron
regulatory proteins-1 and -2 have a molecular mass of 87 and
105 kDa, respectively (24,25). Heterogenous nuclear RNP exist
with molecular masses ranging from 34 to 120 kDa, none
however around 90–100 kDa (26).
Competition experiments using two types of assays and in vitro
transcribed RNA probes have demonstrated that binding of the 93
and 94 kDa proteins to GM-CSF mRNA occurs in a region
designated URE which is separated from the area containing the
AREs (Figs 1, 3 and 4). While the muURE region spans ∼187 nt,
specific protein binding has also been observed to an RNA probe
of ∼60 nt in length. This area, spanning ribonucleotides 497–556
of the murine GM-CSF mRNA, is located within muURE and
includes a TRE. While no such element has been characterized in
the 3′UTR of human GM-CSF mRNA, both the human as well
as the murine protein bound to murine TRE probe. As shown by
northwestern blot assays, the binding of radiolabeled TRE could
be competed by the addition of cold TRE at 103–104-fold molar
excess (Fig. 6A) while a 105-fold molar excess of unrelated
competitor (yeast tRNA) did not prevent complex formation. In
contrast, URE binding was affected by 100-fold cold competitor
suggesting a lower binding specificity for the partial URE probe.
This difference in binding specificity may be explained by the
formation of secondary and tertiary structures that are likely
necessary for protein interaction (27). Computer-aided structure
predictions did not reveal any similarity between the murine and
human URE. Such structures may also be responsible for the
cross-reactivity of the murine protein to the human URE and
vice-versa, because no obvious RNA sequence homology
between the two species has been observed. Furthermore, the
RNA–protein interaction possibly depends on the presence of
multiple binding sites. This would explain the observation that
when a larger target sequence was used as a probe, the interaction
was more specific. The excess rates for cold competition of
labeled RNA we have used in our experiments compare to the
molar excess rates of 100–500-fold reported for other specific
RNA–protein interactions (23,28).
RNase A treatment of RNA–protein complexes of the 93 and
94 kDa proteins with URE yielded protected RNA fragments of
44 and 38 nt, respectively (Fig. 6B). For comparison, some
murine AU-binding proteins of T cell origin protected an area of
63 ribonucleotides (1), and vitellogenin and erythropoietin
mRNA binding proteins protected a region of 27 and 120 nt
within their 3′UTR (29,30). While the length of the protected
fragments may provide information on single- or multifactor
binding, the actual site of RNA–protein interaction is certainly
limited to much smaller regions.
The finding that the 93 and 94 kDa proteins interact specifically
with a sequence element required for TPA- and calcium-ionophore-
mediated stabilization of the mRNA, may imply a role for the two
proteins in regulation of GM-CSF mRNA turnover. An upregulation
of the 94 kDa protein in human Jurkat cells has been observed in
response to PHA stimulation (Fig. 7). In fact, PHA has been
demonstrated to induce release of three major forms of GM-CSF
from human T lymphocytes (13). Therefore, PHA may act in part
via enhancement of protein binding to sequence elements on
huURE and thus increase GM-CSF mRNA stability. The binding
process may be directed by processes such as protein phosphoryla-
tion/dephosphorylation of the binding protein. The fact that no
upregulation has been observed in PHA treated murine EL-4
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cells, nor in TPA-treated Jurkat cells and in a few other cell types
tested, suggests cell- and stimulus-specific differences. Such
cell-specific differences have also been observed for TPA-mediated
stabilization of GM-CSF mRNA. While stabilization was observed
in murine EL-4 cells, no such effect was detected in murine
fibroblasts (14). In addition, GM-CSF mRNA is stable in certain
tumor cell lines whereas in some others it is not (31). These cell
type-specific differences in mRNA turnover may be caused by
the involvement of additional trans-acting regulatory factors
which bind directly to RNA or act via protein–protein interactions
to other RNA-binding proteins. Proteins binding to URE likely
interact with proteins binding to adjacent sequences, such as
ARE, and thus overcome their destabilizing effects. It is also
plausible that the binding of proteins to URE prevents, or hinders,
the interaction between the AREs and destabilizing factors.
The identified proteins bound to mRNA within a region that
contains regulatory sequences and were up-regulated by a stimulus
that promotes GM-CSF expression. These observations suggest
a function of these proteins in mRNA turnover.
ACKNOWLEDGEMENTS
We gratefully acknowledge the expert technical assistance of
Karin Freiburghaus Rohrer and Catherine Solioz-Fehlmann. This
work was supported by grant # 31-36143.92 from the Swiss
National Foundation for Scientific Research and grant #185 from
the Swiss Dental Association.
REFERENCES
1 Bickel,M., Iwai,Y., Pluznik,D.H. and Cohen,R.B. (1992) Proc. Natl. Acad.
Sci. USA, 89, 10001–10005.
2 Bohjanen,P.R., Petryniak,B., June,C.H., Thompson,C.B. and Lindsten,T.
(1991) Mol. Cell. Biol., 11, 3288–3295.
3 Brewer,G. (1991) Mol. Cell. Biol., 11, 2460–2466.
4 Huang,L.Y., Tholanikunnel,B.G., Vakalopoulou,E. and Malbon,C.C.
(1993) J. Biol. Chem., 268, 25769–25775.
5 Levine,T.D., Gao,F., King,P.H., Andrews,L.G. and Keene,J.D. (1993) Mol.
Cell. Biol., 13, 3494–3504.
6 Malter,J.S. (1989) Science, 246, 664–666.
7 Nakagawa,J., Waldner,H., Meyer,M.-S., Hofsteenge,J., Jeno,P. and
Moroni,C. (1995) Proc. Natl. Acad. Sci. USA, 92, 2051–2055.
8 Nanbu,R., Kubo,T., Hashimoto,T. and Natori,S. (1993) J. Biochem., 114,
432–437.
9 Vakalopoulou,E., Schaack,J. and Shenk,T. (1991) Mol. Cell. Biol., 11,
3355–3364.
10 Hua,J. and Paetkau,V. (1996) Nucleic Acids Res., 24, 970–976.
11 Tholanikunnel,B.G., Granneman,J.G. and Malbon,C.C. (1995) J. Biol.
Chem., 270, 12787–12793.
12 Bickel,M., Cohen,R.B. and Pluznik,D.H. (1990) J. Immunol., 145,
840–845.
13 Burgess,A.W., Cebon,J. and Smith,S. (1989) Biochem. Soc. Symp., 55,
57–68.
14 Iwai,Y., Bickel,M., Pluznik,D.H. and Cohen,R.B. (1991) J. Biol. Chem.,
266, 17959–17965.
15 Iwai,Y., Akahane,K., Pluznik,D.H. and Cohen,R.B. (1993) J. Immunol.,
150, 4386–4394.
16 Farrar,J.J., Fuller,F.J., Simon,P.L., Hilfiker,M.L., Stadler,B.M. and
Farrar,W.L. (1980) J. Immunol., 125, 2555–2558.
17 Weiss,A., Wiskocil,R.L. and Stobo,J.D. (1984) J. Immunol., 133, 123–128.
18 Dignam,J.D. (1990) Methods Enzymol., 182, 194–203.
19 Miyatake,S., Otsuka,T., Yokota,T., Lee,F. and Arai,K. (1985) EMBO J., 4,
2561–2568.
20 Wong,G.G., Witek,J.S., Temple,P.A., Wilkens,K.M., Leary,A.C.,
Luxenberg,D.P., Jones,S.S., Brown,E.L., Kay,R.M., Orr,E.C., et al. (1985)
Science, 228, 810–815.
21 Gough,N.M., Metcalf,D., Gough,J., Grail,D. and Dunn,A.R. (1985) EMBO
J., 4, 645–653.
22 Muller,W.E., Slor,H., Pfeifer,K., Huhn,P., Bek,A., Orsulic,S., Ushijima,H.
and Schroder,H.C. (1992) J. Mol. Biol., 226, 721–733.
23 Zhang,W., Wagner,B.J., Ehrenman,K., Schaefer,A.W., DeMaria,C.T.,
Crater,D., DeHaven,K., Long,L. and Brewer,G. (1993) Mol. Cell. Biol., 13,
7652–7665.
24 Rouault,T.A., Tang,C.K., Kaptain,S., Burgess,W.H., Haile,D.J.,
Samaniego,F., McBride,O.W., Harford,J.B. and Klausner,R.D. (1990)
Proc. Natl. Acad. Sci. USA, 87, 7958–7962.
25 Henderson,B.R. and Kuhn,L.C. (1995) J. Biol. Chem., 270, 20509–20515.
26 Dreyfuss,G., Matunis,M.J., Pinol-Roma,S. and Burd,C.G. (1993) Annu.
Rev. Biochem., 62, 289–321.
27 Mattaj,I.W. (1993) Cell, 73, 837–840.
28 Dodson,R.E., Acena,M.R. and Shapiro,D.J. (1995) J. Steroid Biochem.
Mol. Biol., 52, 505–515.
29 Dodson,R.E. and Shapiro,D.J. (1994) Mol. Cell. Biol., 14, 3130–3138.
30 Rondon,I.J., MacMillan,L.A., Beckman,B.S., Goldberg,M.A., Schneider,T.,
Bunn,H.F. and Malter,J.S. (1991) J. Biol. Chem., 266, 16594–16598.
31 Schuler,G.D. and Cole,M.D. (1988) Cell, 55, 1115–1122.
